Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

Knowable economics surpass exciting narratives. If you can’t reliably estimate a firm’s medium-term earnings power, don’t touch it—and be particularly wary in sectors where technological, regulatory, ...

Big Tech stocks were basically the only thing working for investors on Monday, as the S&P 500 seesawed in recent trading and the Dow and Russell 2000 retreated. The Nasdaq Composite has so far been ...

Dow Jones Top Financial Services Headlines at 4 PM ET: Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day. | BOE ... Activist Investors in Kenvue Faced Big Losses.